Watch, listen and learn. Our 2020 AdvanSE session can help you know, and fix, the ways medtech innovators burn cash unnecessarily.
Too many promising medtech innovations and early stage companies fail unnecessarily because they run out of funding before achieving milestones required for next-round investments.
It is possible to know earlier in the process when innovators are burning cash at too high a rate and failure is nearly certain.
Learn from GCMI’s Sarah Cohen, Advanced Catheter Therapies’ Paul Fitzpatrick, Jackson Medical’s Kamil Mahknejia, UVA Licensing and Venture Group’s Andy Krouse from their 2020 Southeast Life Sciences AdvanSE event recorded in November.
Watch, listen and learn:
- Top ways innovators burn cash unnecessarily
- How innovators can know they are wasting time and money prototyping
- How to know when a medtech innovation is ready for preclinical work
- The critical importance of activity sequencing in the medtech innovation pathway
- Critical questions to ask prospective partners in regulatory, IP, engineering and reimbursement
If you have an idea, design or maybe even a prototype for a new technology with medical care potential, it’s never too early to reach out to us. Contact email@example.com and a member of the team will connect with you.
GCMI helps verify, validate and accelerate commercialization of new medical technologies that save lives and improve patient care. From our Northyards and 14th Street facilities in midtown Atlanta, we help find the finish line for medtech innovations at any point on the pathway from bench to bedside.
About Southeast Life Sciences
Following the merger of SEBIO and Southeast Medical Device Association (SEMDA) in February 2020, Southeast Life Sciences brings together life science investors including large strategic medical technology and pharmaceutical companies, the top life science startups from around the southeast and industry professionals that support them like GCMI.